Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.

European journal of clinical pharmacology - 1 Mar 2013

Stringer Frances, Scott Graham, Valbuena Marian, Kinley Judith, Nishihara Mitsuhiro, Urquhart Richard

Abstract excerpt

PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARγ, PPARα, and PPARδ. The compound undergoes phase II biotransformation by conjugation catalyzed by UDP-glucuronosyltransferase (UGT). The aim of this analysis was to explore the influence of genetic polymorphism in UGT on the pharmacokinetics of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Half-Life

Share to Hypoglycemic Agents

Share to Metabolic Clearance Rate

Share to Propionates

Share to Thiazoles

Source

Identifiers

PMID: 22960998
DOI: 10.1007/s00228-012-1382-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.PMID 22960998Read ↗

Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.Semantic proximity Read ↗

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.Semantic proximity Read ↗

UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.Semantic proximity Read ↗

Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.Semantic proximity Read ↗

Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation.Semantic proximity Read ↗

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.Semantic proximity Read ↗

Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.Semantic proximity Read ↗

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.